The microbiome is the natural bacterial colonisation of the body – including skin, gut and stomach. The human microbiome refers to the spectrum of microbes (microbiota) that colonize humans. Microbiome therapies are currently focused on the prevention of C. difficile recurrence. This bacterium is often contracted in hospitals following antibiotic administration or a period of immunosuppression. The global microbiome therapeutics market is set to grow by US$ 918 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 32.5% during the forecast period, according to data and analytics company StrategyHelix. Significant external funding for executing research and therapeutic innovation, increasing adoption of inorganic growth strategies in the market, growing demand for novel therapies to address the unmet needs of many diseases are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for microbiome therapeutics. The global microbiome therapeutics market is segmented on the basis of target therapy area, region. By target therapy area, it is categorized into gastrointestinal diseases, infections, and others. The gastrointestinal diseases segment held the largest market share in 2020. By region, the microbiome therapeutics market is divided into North America, Asia Pacific, Europe, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as 4D Pharma plc, AOBiome Therapeutics Inc., Assembly Biosciences Inc., Eligo Bioscience S.A.S, Finch Therapeutics Group Inc., MaaT Pharma SA, Quorum Innovations LLC, Rebiotix Inc. (Ferring Pharmaceuticals Group), Seres Therapeutics Inc., Synthetic Biologics, Vedanta Biosciences Inc..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the microbiome therapeutics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Target therapy area: gastrointestinal diseases, infections, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the global microbiome therapeutics market
Pinpoint growth sectors and trends for investment
Understand what the future of the global microbiome therapeutics market looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Microbiome Therapeutics Market by Target Therapy Area
4.1 Gastrointestinal Diseases
4.2 Infections
4.3 Others
5. Microbiome Therapeutics Market by Region
5.1 North America
5.2 Asia Pacific
5.3 Europe
5.4 Rest Of The World (Row)
6. Company Profiles
6.1 4D Pharma plc
6.2 AOBiome Therapeutics, Inc.
6.3 Assembly Biosciences, Inc.
6.4 Eligo Bioscience S.A.S
6.5 Finch Therapeutics Group, Inc.
6.6 MaaT Pharma SA
6.7 Quorum Innovations, LLC
6.8 Rebiotix, Inc. (Ferring Pharmaceuticals Group)
6.9 Seres Therapeutics, Inc.
6.10 Synthetic Biologics
6.11 Vedanta Biosciences, Inc.
7. Appendix
7.1 About StrategyHelix
7.2 Disclaimer

USD 2,750

Product Type

Market Research

Release Date

29 May 2021






Global Microbiome Therapeutics Market 2021

Please fill out our form and we will get back to you.


Global Microbiome Therapeutics Market 2021

Please fill out our form and we will get back to you.